Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
Currency:  $ £
Discounted Reports
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare

Global Pharmaceutical & Biotechnology Outlook 2014: Rising Stars

Enquire | Email | Print

Click Here!!! and Get this report in a Combo Package with 20% OFF!!!
Published Date: Jan, 2014
Format: PDF
No of Pages: 113
Select pricing :
Change Currency: EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

Innovations have contributed to the availability of a range of new treatments for diseases resulting in improvement in the length and quality of life and reduced disease burden for individuals and society.  However, the need for innovative therapies for unmet needs /challenging diseases continues to grow, accelerating the pace of drug development directly or through partnership/ in-licensing. We expect innovation and improved drugs therapies through novel target discovery and technology platforms to continue to flow from the backyards of small research focused companies (Rising Stars, RS – non-profitable biotech companies) in coming years.  

Approval of new drugs, successful launches, maturing pipeline sustained the growth trajectory of biotech companies resulting in successful IPOs. We expect the optimism to percolate further into companies with novel technology platforms and targets. For more details on the trend in drug approvals, upcoming milestones and M&A in coming years please see Global Pharmaceutical and Biotechnology Outlook 2014 :Rising Stars

Macro Analysis
· Drug Approval in 2013
· Performance of IPO’S: 2013
· Drug Launches: 2014/15
· Unmet Need of Innovators - Launched and Pipeline Unpartnered Compounds
· Competition can reduce the life span of innovative patented drugs- Competitive landscape of
PI3K, Jak and BTK inhibitors in clinical development
· Resisting resistance – Global threat and Action taken
· Oral vs. Injectables – Oral drugs for MS, RA and Psoriasis
· Targeting Unmet Need on Hematological Malignancies- RRMM, RRMDS

In-depth Company Analysis –

In-depth Company Analysis and Reports on
1. Ablynx- Nanobodies – Turnarond on the Horizon!

1.1 Key Attributes- Novel Technology Platform, Partnership and Drug Portfolio
1.2 Background on the Nanobody technology platform ,
1.3 Clinical data of key drugs in the pipeline- ALX0061—(IL6R Ab), ALX-0171 (Anti RSV)
1.4 Key Milestones

2. Ambit Biosciences- Quizartinib in RR-AML = Delayed but not Dead!
2.1 Tapping the Unmet Need in RRAML with Quizartinib
2.2 Background and Clinical Data of Quizartinib
2.3 Competitive Landscape in RRAML
2.4 Partnership opportunity and attributes of kinase technology platform and early drugs in pipeline
2.5 Key Milestones

3. Basilea- “Drugs for Bad Bugs” Isavuconazole– Watch out for ACTIVE and VITAL
3.1 Key Driver of 2014 – PhIII outcome of Antifungal - Isavuconazole
3.2 Competitive Landscape for Antifungals
3.3 Ceftobiprole- Revived with approval in EU for Nocosomial Infections-Commercial Opportunity
3.4 Other Drugs in Pipeline
3.5 Key Milestones

4.Cempra (CEMP)
4.1. Key Drugs – Solithromycin, TAKSTA
4.2. Market Opportunity for Next Generation Macrolides
4.3. Background
4.4. Clinical Updates – Solithromycin,
4.5. TAKSTA- Orphan Drug Status in Prosthetic Joint Infection
4.6. Clinical Data and Trial Design
4.7. Comparison- Linezolid vs. Taksta
4.8. Market Opportunity
4.9. Key Milestones

5. Endocyte-
5.1 The Power and Opportunity for Small Drug Conjugates (SMDC) technology Platform
5.2 Vintafolide- in PROC and NSCLC- EU Conditional approval a Wild card
5.3 Clinical Data and Trial details
5.4 Background and Application of SMDC technology Platform
5.5 Pipeline and Partnership Opportunity
5.6 Key Milestones

6. Enanata- The Party to Continue in 2014 – 2nd in the Oral IFN-free HCV Drug Race
6.1 ABT-450- Blockbuster Opportunity despite competition from Sovaldi!
6.2 Clinical Data and Trial Details- SAPPHIRE 1, II
6.3 Competitive Landscape in Oral, IFN Free HCV Treatment Options
6.4 Comparative Clinical data of Oral, IFN free drug combinations for HCV
6.5 Background –Drugs in Pipeline and Partnership with Abbvie, Novartis.

7. Galapagos- Drug Discovery platform driving robust Partnership –AbbVie, GSK, Janssen, Servier..
7.1. Drug Discovery platform driving robust Partnership –AbbVie, GSK, Janssen, Servier..
7.2. GLPG0634- Oral Jak Inhibitor- Key Attributes- Safety and Efcacy
7.3. PhIII Trial Design- DARWIN1 and 2
7.4. Clinical Data Comparison – Select Oral RA Drugs
7.5. Other Drugs in Pipeline
7.6. Entering New Therapy Areas-, Cystic Fibrosis, Anti-infectives
7.7. Key Milestones

8. Incyte - INCB39110 – Another JAK-Fruit in INCY's Bucket 
Leader in the Jak- 2 Inhibitor Space
8.1. JAKAFI – Label Expansion- Pancreatic Cancer and other tumors
8.2. Another Promising unpartnered Jak2 inhibitor- INCB-39110 in Psoraisis and MF
8.3. Baricitinib oral RA drug in PhIII. Clinical data and Trial Design
8.4. Other Mid- to Early-stage Pipeline-
8.5. Clinical Data Comparison: in RA
8.6. Competitive Landscape in Plaque Psoriasis

9. ISIS - Beyond KYNAMRO – Targeting Other Niche Indications
9.1 Next Set of Commercial opportunities- orphan drugs
9.2 Robust Partnership and Pipeline
9.3 Comparative data in Hypercholesterolemia
9.4 Key Milestones

10. Morphosys - MOR103/ MOR202 – Partnering is the Beginning of a New Phase of Growth
10.1 Recognition by Global Partners- Celgene (MOR 202), GSK (MOR 103)
10.2 Maturing Pipeline and Technology Platform
10.3 Key Milestones

11. Onconova- ONTIME – Holds the Key!
11.1 Estybon in RRMDS- Background and Clinical data
11.2 Trial Design and Label Expansion Potential
11.3 Competition in RR MDS/AML and Market Opportunity
11.4 Other Drugs in Pipeline
11.5 Partnership with Baxter and Symbio
11.6 Key Milestones

12. Pharmacyclics- Ibrutinib Therapy: A Game Changer for Leukemia
12.1 IMBRUVICA- Leads the way in Efcacy, Safety in Leukemia
12.2 Commercial Potential and Clinical Data
12.3 Ongoing Trials in CLL, NHL, DLBCL
12.4 Clinical Data Comparison in CLL/SLL
12.5 Competitive Landscape – BTK PI3K inhibitors
12.6 Partnership with J&J- Deal terms
12.7 Key Milestones

13. SymBio (4582 JP) Future Growth-TREAKISYM’s Label Expansion and Rigosertib’s Success
13.1 Rigosertib-ONTIME dependence,
13.2 TREAKISYM- Lable expansion
13.3 Background
13.4 Competition From Drugs in the Pipeline FOR RR/HR MDS

Industry Tables
1. Drug Clinical Milestones
2. Drug Launch Table- 2014

Related Reports:  


Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.


Top Go to top of the page

product id: 364880, price: INR 151309, MP Advisors

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
About Trust Online